Federal Register / Vol. 66, No. 122 / Monday, June 25, 2001 / Notices 33713

enhancing cooperative activities

between Federal and private sector

research organizations. In addition, the

National Parks Omnibus Management

Act of 1998 (Pub. L. 105–391)

specifically authorizes the negotiation of

‘‘equitable, efficient benefits-sharing

arrangements’’ between units of the

National Park System and the research

community.

NPS regulations provide that a park

superintendent may issue a permit to a

qualifying researcher when it

determined that ‘‘public health and

safety, environmental or scenic values,

natural or cultural resources, scientific

research, implementation of

management responsibilities, proper

allocation and use of facilities, or the

avoidance of conflict among visitor use

activities will be adversely impacted’’

(36 CFR 1.6(a)). Through a public

process, this environmental assessment

will examine potential environmental

impacts of various methods of

implementing the provisions of law that

authorizes benefits-sharing agreements

while ensuring the integrity of

resources.

A newsletter and web site have been

prepared with additional information

concerning this assessment. Copies of

that information may be obtained online

at www.nature.nps.gov/benefitsharing or

by contacting: NPS Benefits Sharing

Team, P.O. Box 168, Yellowstone

National Park, WY, 82190; telephone

307–344–2203. Comments may be

submitted by any one of several

methods. You may mail comments to:

National Park Service. Benefit-Sharing

Environmental Assessment, P.O. Box

168, Yellowstone National Park, WY

82190. You may also email comments to

Benefits EA@nps.gov, or submit them

online at www.nature.nps.gov/

benefitssharing. NPS practice is to make

comments, including the names and

address of respondents, available for

public review during regular business

hours. Individual respondents may

request that NPS withhold their address

from the record, which will be honored

to the extent allowable by law. There

also may be circumstances in which

NPS would withhold from the record a

respondent’s identity, to the extent

allowable by law. If you wish the NPS

to withhold your name and/or address,

you must state this prominently at the

beginning of your comments. NPS will

make all submissions from

organizations and businesses, and from

individuals identifying themselves as

representatives or officials or

organizations or businesses, available

for public inspection in their entirety.

DATES: Comments on the potential scope

of the assessment, alternatives to be

considered, impacts to be addressed,

and any other relevant related issues

should be submitted on or before

August 9, 2001.

FOR FURTHER INFORMATION CONTACT: Sue

Mills, National Park Service Benefits

Sharing Team, P.O. Box 168,

Yellowstone National Park, WY 82190;

telephone 307–344–2203.

Dated: June 1, 2001.

Abigail Miller,

Acting Associate Director, Natural Resources

Stewardship and Science.

[FR Doc. 01–15559 Filed 6–22–01; 8:45 am]

BILLING CODE 4310–70–M

DEPARTMENT OF THE INTERIOR

Office of Surface Mining Reclamation

and Enforcement

Notice of Proposed Information

Collection

AGENCY: Office of Surface Mining

Reclamation and Enforcement.

ACTION: Notice and request for

comments.

SUMMARY: In compliance with the

Paperwork Reduction Act of 1995, the

Office of Surface Mining Reclamation

and Enforcement (OSM) is announcing

its intention to renew authority to

collect information for a series of

customer surveys to evaluate OSM’s

performance in meeting the

performance goals outlined in its annual

plans developed pursuant to the

Government Performance and Results

Act (GPRA). The Office of Management

and Budget (OMB) previously approved

the collection and assigned it clearance

number 1029–0114.

DATES: Comments on the proposed

information collection must be received

by August 24, 2001, to be assured of

consideration.

ADDRESSES: Comments may be mailed to

John A. Trelease, Office of Surface

Mining Reclamation and Enforcement,

1951 Constitution Ave., NW., Room

210–SIB, Washington, DC 20240.

Comments may also be submitted

electronically to jtrerleas@osmre.gov.

FOR FURTHER INFORMATION CONTACT: To

request a copy of the information

collection request, explanatory

information and related form, contact

John A. Trelease, at (202) 208–2783.

SUPPLEMENTARY INFORMATION: OMB

regulations at 5 CFR 1320, which

implementing provisions of the

Paperwork Reduction Act of 1995 (Pub.

L. 104–13), require that interested

members of the public and affected

agencies have an opportunity to

comment on information collection and

recordkeeping activities (see 5 CFR

1320.8 (d)). This notice identifies

information collections that OSM will

be submitting to OMB for approval. An

agency may not conduct or sponsor, and

a person is not required to respond to,

a collection of information unless it

displays a currently valid OMB control

number. The OMB control number for

this collection of information is 1029–

0114 and is on the forms along with the

expiration date. OSM will request a 3-

year term of approval for this

information collection activity.

Comments are invited on: (1) The

need for the collection of information

for the performance of the functions of

the agency; (2) the accuracy of the

agency’s burden estimates; (3) ways to

enhance the quality, utility and clarity

of the information collection; and (4)

ways to minimize the information

collection burden on respondents, such

as use of automated means of collection

of the information. A summary of the

public comments will accompany

OSM’s submission of the information

collection request to OMB.

This notice provides the public with

60 days in which to comment on the

following information collection

activity:

Title: Technical Evaluations Series.

OMB Control Number: 1029–0114.

Summary: The series of surveys are

needed to ensure that technical

assistance activities, technology transfer

activities and technical forums are

useful for those who participate or

receive the assistance. Specifically,

representatives from State and Tribal

regulatory and reclamation authorities,

representatives of industry,

environmental or citizen groups, or the

public, are the recipients of the

assistance or participants in these

forums. These surveys will be the

primary means through which OSM

evaluates its performance in meeting the

performance goals outlines in its annual

plans developed pursuant to the

Government Performance and Results

Act.

Bureau Form Number: None.

Frequency of Collection: Once.

Description of Respondents: 26 State

and Tribal governments, industry

organizations and individuals who

request information or assistance.

Total Annual Responses: 750.

Total Annual Burden Hours: 125.

33714 Federal Register / Vol. 66, No. 122 / Monday, June 25, 2001 / Notices

Dated: June 13, 2001.

Richard G. Bryson,

Chief, Division of Regulatory Support.

[FR Doc. 01–15894 Filed 6–22–01; 8:45 am]

BILLING CODE 4310–05–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated January 25, 2001, and

published in the Federal Register on

February 14, 2001, (66 FR 10320),

Cerilliant Corporation, 14050 Summit

Drive #121, P.O. Box 201088, Austin,

Texas 78708–0189, made application to

the Drug Enforcement Administration

(DEA) to be registered as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Cathinone (1235) .......................... I

Methcathinone (1237) .................. I

N-Ethylamphetamine (1475) ........ I

N, N-Dimethylamphetamine

(1480).

I

Aminorex (1585) ........................... I

4-Methylaminorex (cis isomer)

(1590).

I

Gamma hydroxybutyric acid

(2010).

I

Methaqualone (2565) ................... I

Alpha-Ethyltryptamine (7249) ....... I

Lysergic acid diethylamide (7315) I

Tetrahydrocannabinols (7370) ..... I

Mescaline (7381) .......................... I

3,4,5-Trimethoxyamphetamine ..... I

4-Bromo-2, 5-

dimethoxyamphetamine (7390).

I

4-Bromo-2, 5-

dimethoxyphenethylamine

(7392).

I

4-Methyl-2, 5-

dimethoxyamphetamine (7395).

I

2, 5-Dimethoxyamphetamine

(7396).

I

2, 5-Dimethoxy-4-

ethylamphetamine (7399).

I

3, 4-Methylenedioxyamphetamine

(7400).

I

5-Methoxy-3, 4-

methylenedioxyamphetamine

(7401).

I

N-Hydroxy-3, 4-

methylenedioxyamphetamine

(7402).

I

3, 4-Methylenedioxy-Nethylamphetamine (7404).I

3, 4-

Methylenedioxymethamphetamine (7405).

I

4-Methoxyamphetamine (7411) ... I

Bufotenine (7433) ......................... I

Diethyltryptamine (7434) .............. I

Dimethyltryptamine (7435) ........... I

Psilocybin (7437) .......................... I

Psilocyn (7438) ............................. I

Acetyldihydrocodeine (9051) ........ I

Drug Schedule

Benzylmorphine (9052) ................ I

Codeine-N-oxide (9053) ............... I

Dihydromorphine (9145) ............... I

Heroin (9200) ............................... I

Morphine-N-oxide (9307) ............. I

Normorphine (9313) ..................... I

Pholcodine (9314) ........................ I

Acetylmethadol (9601) ................. I

Allyprodine (9602) ........................ I

Alphacetylmethadol except LevoAlphacetylmethadol (9603).I

Alphameprodine (9604) ................ I

Alphamethadol (9605) .................. I

Betacetylmethadol (9607) ............ I

Betameprodine (9608) .................. I

Betamethadol (9609) .................... I

Betaprodine (9611) ....................... I

Hydromorphinol (9627) ................. I

Noracymethadol (9633) ................ I

Norlevorphanol (9634) .................. I

Normethadone (9635) .................. I

Trimeperidine (9646) .................... I

Para-Fluorofentanyl (9812) .......... I

3-Methylfentanyl (9813) ................ I

Alpha-methylfentanyl (9814) ........ I

Acetyl-alpha-methylfentanyl

(9815).

I

Beta-hydroxyfentanyl (9830) ........ I

Beta-hydroxy-3-methylfentanyl

(9831).

I

Alpha-Methylthiofentanyl (9832) ... I

3-Methylthiofentanyl (9833) .......... I

Thiofentanyl (9835) ...................... I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Phenmetrazine (1631) .................. II

Methylphenidate (1724) ................ II

Amobarbital (2125) ....................... II

Pentobarbital (2270) ..................... II

Secobarbital (2315) ...................... II

Glutethimide (2550) ...................... II

Nabilone (7379) ............................ II

1-Phenylcyclohexylamine (7460) II

Phencyclidine (7471) .................... II

1-

Piperidinocyclohexanecarbonitrile (8603).

II

Alphaprodine (9010) ..................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Dihydrocodeine (9120) ................. II

Oxycodone (9143) ........................ II

Hydromorphone (9150) ................ II

Diphenoxylate (9170) ................... II

Benzoylecgonine (9180) ............... II

Ethylmorphine (9190) ................... II

Hydrocodone (9193) ..................... II

Levomethorphan (9210) ............... II

Levorphanol (9220) ...................... II

Isomethadone (9226) ................... II

Meperidine (9230) ........................ II

Methadone (9250) ........................ II

Methadone-intermediate (9254) ... II

Morphine (9300) ........................... II

Thebaine (9333) ........................... II

Levo-alphacetylmethadol (9648) .. II

Oxymorphone (9652) ................... II

Noroxymorphone (9668) .............. II

Alfentanil (9737) ........................... II

Sufentanil (9740) .......................... II

Fentanyl (9801) ............................ II

The firm plans to manufacture small

quantities of the listed controlled

substances to make deuterated and nondeuterated drug reference standards

which will be distributed to analytical

and forensic laboratories for drug testing

programs.

No comments or objections have been

received.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Cerilliant Corporation to

manufacture the listed controlled

substances is consistent with the public

interest at this time. DEA has

investigated Cerilliant Corporation to

ensure that the company’s registration is

consistent with the public interest. This

investigation included inspection and

testing of the company’s physical

security systems, verification of the

company’s compliance with state and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. § 823

and 28 CFR §§ 0.100 and 0.104, the

Deputy Assistant Administrator, Office

of Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic classes of

controlled substances listed above is

granted.

Dated: June 4, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 01–15835 Filed 6–22–01; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances;

Notice of Registration

By Notice dated November 8, 2000,

and published in the Federal Register

on November 28, 2000 (65 FR 70936),

and by Notice dated December 14, 2000,

and published in the Federal Register

on January 10, 2001 (66 FR 2003),

Cerilliant Corporation, 14050 Summit

Drive #121, P.O. Box 80189, Austin, TX

78708–0189, made application by

renewal to the Drug Enforcement

Administration to be registered as an

importer of the basic classes of

controlled substances listed below:

Drug Schedule

Cathinone (1235) .......................... I

Methcathinone (1237) .................. I

N-Ethylamphetamine (1475) ........ I

Gamma hydroxybutyric acid

(2010).

I

Ibogaine (7260) ............................ I